| Assessment of Sleep Disturbance in Alzheimer Disease (NCT00831298) | Centre Hospitalier Universitaire de Nice | 2010-07-01 |
| Neuro Imaging and Multimodal Alzheimer's Disease (NCT02839187) | University Hospital, Toulouse | 2010-06-01 |
| Study of Adherence and Effects of Balance Exercices (SIEL BLEU Associatio) (NCT01314638) | University Hospital, Angers | 2010-05-01 |
| Eye Movement Recording as an Early Differential Diagnostic Tool for Alzheimer/Depression (NCT01434940) | Centre Hospitalier Universitaire de Besancon | 2010-04-01 |
| Evaluation of [18F] PBR111 and PET as a Marker of Inflammation in Subjects With Neurological Conditions (NCT01209156) | Institute for Neurodegenerative Disorders | 2010-03-01 |
| Comparison of 3 Learning Methods to Improve Independent Activities of Daily Living (IADLs) in Alzheimer Disease (NCT01095718) | Department of Clinical Research and Innovation | 2010-03-01 |
| Multiple Dose Japanese Bridging Study (NCT01057030) | Bristol-Myers Squibb | 2010-03-01 |
| Alzheimer's Disease Acitretin Medication (NCT01078168) | K. Lieb | 2010-03-01 |
| Cerebro Spinal Fluid Collection (CSF) (NCT04844060) | University Hospital, Strasbourg, France | 2010-02-01 |
| Physical Exercise as an Additional Treatment for Alzheimer Disease (NCT01515982) | Universidade Federal do Rio de Janeiro | 2010-02-01 |
| Deep Brain Stimulation (DBS) of the Nucleus Basalis Meynert (NBM) to Treat Cognitive Deficits in Light to Moderate Alzheimer's Disease (NCT01094145) | University of Cologne | 2010-01-01 |
| Drug-Drug Interaction Study With Aricept® (Donepezil) (NCT01042314) | Bristol-Myers Squibb | 2010-01-01 |
| National Bank Alzheimer (NCT03687112) | Centre Hospitalier Universitaire de Nice | 2010-01-01 |
| TMS Stimulation and Cognitive Training in Alzheimer Patients (NCT01168245) | Neuronix Ltd | 2010-01-01 |
| Drug-Drug Interaction to Study the Effect of BMS-708163 on Pharmacokinetics (PK) of Galantamine Extended Release (ER) (NCT01039194) | Bristol-Myers Squibb | 2010-01-01 |
| A Long-Term Safety And Tolerability Extension Study Of Bapineuzumab In Alzheimer Disease Patients (NCT00998764) | Pfizer | 2009-12-01 |
| Clinical Evaluation of Florbetapir F 18 (18F-AV-45) (NCT01518374) | Avid Radiopharmaceuticals | 2009-12-01 |
| To Investigate the Safety and Tolerability of Repeated Subcutaneous Injections of CAD106 in Alzheimer's Patients (NCT01023685) | Novartis | 2009-12-01 |
| A Long-Term Safety And Tolerability Study Of Bapineuzumab In Alzheimer Disease Patients (NCT00996918) | Pfizer | 2009-12-01 |
| Long Term Extension Study Evaluating Safety, Tolerability and Immunogenicity Of ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease (NCT00955409) | Pfizer | 2009-11-05 |
| Gait and Alzheimer Interaction Tracking (GAIT) Study (NCT01315717) | University Hospital, Angers | 2009-11-01 |
| Phase III Study of Florbetaben (BAY94-9172) PET Imaging for Detection/Exclusion of Cerebral β-amyloid Compared to Histopathology (NCT01020838) | Lantheus Biosciences Ltd. | 2009-11-01 |
| Supporting Caregivers of Persons With Dementia: A Pilot Study (NCT00908492) | McMaster University | 2009-11-01 |
| Evaluation of [18F] PBR06 and PET as a Marker of Inflammation in Subjects With Neurological Conditions (NCT01028209) | Institute for Neurodegenerative Disorders | 2009-11-01 |
| A Longitudinal Multidimensional Population Study on Brain Aging (NCT01345110) | Fondazione Golgi Cenci | 2009-11-01 |
| Efficacy and Safety of Curcumin Formulation in Alzheimer's Disease (NCT01001637) | Jaslok Hospital and Research Centre | 2009-10-01 |
| Safety and Efficacy of Positron Emission Tomography Imaging With MNI-513 (NCT01000870) | Institute for Neurodegenerative Disorders | 2009-10-01 |
| To Investigate the Safety and Tolerability of Repeated Subcutaneous Injections of CAD106 in Alzheimer's Patients (NCT00956410) | Novartis | 2009-09-01 |
| Pregnenolone Sulfate an Early Marker of the Memory Loss in Alzheimer's Disease (NCT00912886) | Assistance Publique - Hôpitaux de Paris | 2009-09-01 |
| A Phase 3 Efficacy Study Of Dimebon In Patients With Moderate To Severe Alzheimer's Disease (NCT00912288) | Pfizer | 2009-09-01 |
| Effect on the Electrocardiographic QT Interval Corrected for Heart Rate (QTc) in Healthy Subjects (NCT00979316) | Bristol-Myers Squibb | 2009-09-01 |
| Evaluation of [18F] FEPPA and PET Imaging as a Marker of Inflammation in Subjects With Neurological Conditions (NCT00970333) | Institute for Neurodegenerative Disorders | 2009-08-01 |
| Follow-up Study of the Alzheimer's Disease Anti-Inflammatory Prevention Trial (NCT01417130) | Seattle Institute for Biomedical and Clinical Research | 2009-08-01 |
| A Long Term Extension Study Evaluating ACC-001 With QS-21 in Subjects With Mild to Moderate Alzheimer's Disease (NCT00960531) | Pfizer | 2009-07-01 |
| A Proof of Concept Study of the Prevention of Mild Cognitive Impairment and Eventual Alzheimer's Disease Using F18 Flutemetamol (NCT03274817) | NYU Langone Health | 2009-06-18 |
| Assessment of Social-emotional Functioning in Neurological Diseases (NCT01339130) | Centre Hospitalier Universitaire, Amiens | 2009-06-01 |
| Study Evaluating The Long-Term Safety And Efficacy Of Subcutaneous Bapineuzumab (NCT00916617) | Pfizer | 2009-06-01 |
| Study Comparing 3 Dosage Levels Of SAM-531 In Outpatients With Mild To Moderate Alzheimer Disease (NCT00895895) | Pfizer | 2009-05-01 |
| Study Evaluating How Quickly And To What Extent The 14-Carbon-SAM-531 Is Absorbed/Converted/Eliminated In Male Subjects (NCT00906191) | Wyeth is now a wholly owned subsidiary of Pfizer | 2009-05-01 |
| Evaluation of Alteration by Magnetic Resonance Imaging (MRI) in Dementia Among Elderly Subjects (NCT00951197) | University Hospital, Bordeaux | 2009-04-01 |
| Semantic Memory, Financial Capacity, and Brain Perfusion in Mild Cognitive Impairment (MCI) (CASL) (NCT00880555) | VA Office of Research and Development | 2009-04-01 |
| Drug-Drug Interaction (DDI) w/Ketoconazole or Fluconazole (NCT00860275) | Bristol-Myers Squibb | 2009-04-01 |
| A PET Brain Imaging Study of mGluR5 in Subjects With Neuropsychiatric Conditions (NCT00870974) | Institute for Neurodegenerative Disorders | 2009-03-01 |
| Evaluation of Apathy Using Attentional Reaction Test in Neurodegenerative Diseases (NCT00833274) | Centre Hospitalier Universitaire de Nice | 2009-02-01 |
| Dimebon (PF-01913539)-Digoxin Drug-Drug Interaction Study In Healthy Subjects (NCT00831506) | Pfizer | 2009-02-01 |
| The PACO Study ("Personnalité Alzheimer COmportement") (NCT01297140) | Hospices Civils de Lyon | 2009-01-01 |
| Multiple Dose Study Evaluating the Safety and Tolerability of NSA-789 (NCT00795730) | Wyeth is now a wholly owned subsidiary of Pfizer | 2009-01-01 |
| Zolpidem CR and Hospitalized Patients With Dementia (NCT00814502) | Massachusetts General Hospital | 2008-12-01 |
| Study Evaluating ACC-001 in Japanese Patients With Mild To Moderate Alzheimer's Disease (NCT00752232) | Pfizer | 2008-12-01 |
| A Phase 1 Study To Evaluate The Effect Of Dimebon On The Pharmacokinetics Of Dextromethorphan (NCT00788047) | Pfizer | 2008-11-01 |
| Study Evaluating Bapineuzumab In Alzheimer Disease Subjects (NCT00663026) | Pfizer | 2008-11-01 |
| Study Evaluating The Potential Interaction Between Verapamil Immediate Release And SAM-531 When Co-Administered (NCT00745576) | Wyeth is now a wholly owned subsidiary of Pfizer | 2008-10-01 |
| Pilot Study of the Effects of Resveratrol Supplement in Mild-to-moderate Alzheimer's Disease (NCT00743743) | Medical College of Wisconsin | 2008-09-01 |
| Drug Interaction Study With a Potential Alzheimer's Disease Compound (NCT00726726) | Bristol-Myers Squibb | 2008-08-01 |
| Study Evaluating Safety, Tolerability and Pharmacokinetics of Single and Multiple Dose of SAM-531 (NCT00726115) | Wyeth is now a wholly owned subsidiary of Pfizer | 2008-08-01 |
| Phase II Study of Florbetaben (BAY 94-9172) PET Imaging for Detection/Exclusion of Cerebral β-amyloid in Patients With Probable Alzheimer's Disease Compared to Healthy Volunteers (NCT00750282) | Lantheus Biosciences Ltd. | 2008-08-01 |
| Study Evaluating PAZ-417 in Cerebrospinal Fluid in Subjects With Alzheimer's Disease (NCT00739037) | Wyeth is now a wholly owned subsidiary of Pfizer | 2008-08-01 |
| Safety and Tolerability of Repeated Subcutaneous Injections of CAD106 in Mild Alzheimer's Patients. (NCT00733863) | Novartis | 2008-07-01 |
| Randomized Trial of Exercise and Social Interaction in a Community-Based Sample of Non-Demented Chinese Elders (NCT01696019) | University of South Florida | 2008-07-01 |
| Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients (NCT00667810) | Pfizer | 2008-06-01 |
| Florbetaben (BAY94-9172) PET (Positron Emission Tomography) Imaging in MCI (Mild Cognitive Impairment) Patients (NCT01138111) | Lantheus Biosciences Ltd. | 2008-06-01 |
| PET Study With 11 C-PIB to Evaluate Amyloid Protein Deposits in Mild Cognitive Disorder, Alzheimer's Disease and Early Frontotemporal Degeneration. (NCT06179979) | IRCCS San Raffaele | 2008-05-17 |
| P-glycoprotein Function in Brain Diseases (NCT00677885) | National Institute of Mental Health (NIMH) | 2008-05-09 |
| Transcranial Magnetic Stimulation in Mild Cognitive Impairment and Alzheimer Disease (NCT04771845) | The New York Memory Services | 2008-05-01 |
| Study Evaluating the Safety, Tolerability and Activity of One Dose of PAZ-417 Given to Healthy Japanese Subjects (NCT00684710) | Wyeth is now a wholly owned subsidiary of Pfizer | 2008-04-01 |
| Study Evaluating Safety of GSI 136 in Young and Elderly Japanese Males (NCT00719394) | Wyeth is now a wholly owned subsidiary of Pfizer | 2008-03-01 |
| Evaluation of [123I] MNI-330 and SPECT as a Marker of Beta-amyloid Protein Deposition (NCT00657813) | Institute for Neurodegenerative Disorders | 2008-03-01 |
| A Study of Two Doses of 18F-AV-45 in Alzheimer's Disease and Healthy Volunteers (NCT01565330) | Avid Radiopharmaceuticals | 2008-03-01 |
| Study GSI-136 in Healthy Young and Healthy Elderly Subjects (NCT00718731) | Wyeth is now a wholly owned subsidiary of Pfizer | 2008-03-01 |
| Far Infrared Treatment for Alzheimer's Disease (NCT00599469) | GAAD Medical Research Institute Inc. | 2008-02-01 |
| Early Diagnosis of Alzheimer-like Dementia: Benefit of MRI and PET Imaging (NCT01815112) | Centre Hospitalier Universitaire, Amiens | 2008-02-01 |
| Modafinil Treatment for Sleep/Wake Disturbances in Older Adults (NCT00626210) | VA Palo Alto Health Care System | 2008-02-01 |
| Pharmacokinetic Comparisons of Two Donepezil Formulations (NCT01297036) | Korea University Anam Hospital | 2008-01-01 |
| Evaluation of [123I]CLINDE and SPECT as a Marker of Inflammation in Subjects With PD or AD and in Healthy Subjects (NCT00612872) | Institute for Neurodegenerative Disorders | 2008-01-01 |
| Study Evaluating the Safety and Efficacy of Bapineuzumab in Alzheimer Disease Patients (NCT00676143) | Pfizer | 2008-01-01 |
| Gait as Predictor of Dementia and Falls. The Gait and Brain Cohort Study (NCT03020381) | Manuel Montero Odasso | 2007-12-01 |
| ELND005 in Patients With Mild to Moderate Alzheimer's Disease (NCT00568776) | OPKO Health, Inc. | 2007-12-01 |
| Study Evaluating Potential Pharmacokinetic (PK) Interaction Between Lecozotan and Digoxin (NCT00563732) | Wyeth is now a wholly owned subsidiary of Pfizer | 2007-12-01 |
| Study Evaluating ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease (NCT00498602) | Pfizer | 2007-11-01 |
| The Clinical Study of Pitavastatin Treatment for Group of Mild to Moderate Alzheimer's Disease (NCT00548145) | Osaka University | 2007-11-01 |
| Quality Of Life Assessment In Alzheimer's Disease (AD) Patients Receiving Aricept Tablets (NCT01089582) | Pfizer | 2007-11-01 |
| A Study of 18F-AV-45 in Healthy Volunteers (NCT01564706) | Avid Radiopharmaceuticals | 2007-10-01 |
| Evaluation of [123I] MNI-308 and SPECT as a Marker of Beta-amyloid Protein Deposition in AD Subjects Compared to HC (NCT00544453) | Molecular NeuroImaging | 2007-10-01 |
| Non Pharmacological Management of Behavioural Symptoms in Nursing Home (NCT00824967) | Centre Hospitalier Universitaire de Nice | 2007-10-01 |
| Low-Dose Opiate Therapy for Discomfort in Dementia (L-DOT) (NCT00385684) | VA Office of Research and Development | 2007-10-01 |
| Evaluation of [123I] AV51 and SPECT as a Marker of Beta-amyloid Protein Deposition in Subjects With Alzheimer Disease in Comparison to Healthy Subjects (NCT00556660) | Institute for Neurodegenerative Disorders | 2007-09-01 |
| Magnetic Resonance Spectroscopy Study of Memantine in Alzheimer's Disease (NCT00551161) | Northwell Health | 2007-08-01 |
| Evaluation of [123I] AV94 and SPECT in Subjects With Alzheimer Disease in Comparison to Healthy Subjects (NCT00605059) | Institute for Neurodegenerative Disorders | 2007-08-01 |
| Evaluation of [123I] AV151 and SPECT in Subjects w/ AD in Comparison to Healthy Subjects (NCT00605046) | Institute for Neurodegenerative Disorders | 2007-08-01 |
| Proof of Concept Study of Cognitive Improvement in Patients With Alzheimer's Disease (NCT00501111) | AstraZeneca | 2007-07-01 |
| Study Evaluating the Safety,Tolerability, PK and PD of SAM-531 in the Subjects With Mild to Moderate Alzheimer's Disease (NCT00481520) | Wyeth is now a wholly owned subsidiary of Pfizer | 2007-06-01 |
| Comparative Efficacy, Safety, and Tolerability of Rivastigmine 10 and 15 cm^2 Patch in Patients With Alzheimer's Disease (AD) Showing Cognitive Decline (NCT00506415) | Novartis Pharmaceuticals | 2007-06-01 |
| Study Comparing Lecozotan SR Two 5-mg Tablets Vs. Lecozotan SR One 10-mg Tablet in Healthy Subjects (NCT00494962) | Wyeth is now a wholly owned subsidiary of Pfizer | 2007-06-01 |
| A Preliminary Study of 18F-AV-45 in Alzheimer's Disease and Healthy Elderly Volunteers (NCT01565291) | Avid Radiopharmaceuticals | 2007-06-01 |
| Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SAM-315 (NCT00474552) | Wyeth is now a wholly owned subsidiary of Pfizer | 2007-06-01 |
| Study Evaluating the Effect of Lecozotan SR on the QTc Interval (NCT00499642) | Wyeth is now a wholly owned subsidiary of Pfizer | 2007-06-01 |
| Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of SAM-531 (NCT00479349) | Wyeth is now a wholly owned subsidiary of Pfizer | 2007-05-01 |
| Study Evaluating GSI-953 in Healthy Young and Alzheimer's Patients (NCT00479219) | Wyeth is now a wholly owned subsidiary of Pfizer | 2007-05-01 |
| Study Evaluating Safety, Tolerability, And Immunogenicity Of ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease (NCT00479557) | Pfizer | 2007-05-01 |
| Clinical Trial on Alzheimer Disease, Presbycusis and Hearing Aids (NCT00488007) | Hospices Civils de Lyon | 2007-05-01 |